Clinical Trial Update: Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results evaluate the efficacy and safety of combining ibrutinib (PCI-32765) with ofatumumab in B-cell chronic lymphocytic leukemia and related d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Richter Syndrome
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (Imbruvica) (Ibrutinib)
• Ofatumumab (Arzerra) (Ofatumumab)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-04-16